Business
CRO Appointment
CRO Appointment.
About this update from Gunsynd Plc
[{"type":"text","content":"\n Syntopix Group plc\n08 May 2007\n\n\n\nFor Immediate Release 8 May 2007\n\n SYNTOPIX GROUP PLC\n ('Syntopix' or 'the Group')\n \n AGREEMENT TO COMMENCE COSMETIC TRIALS\n\nSyntopix Group plc (AIM: SYN), the drug discovery and development group focused\non dermatological diseases, is pleased to announce that it has signed an\nagreement with the Germany-based contract research organisation Bioskin, which\nwill conduct trials on behalf of the Company with the objective of identifying\npotential cosmetic treatments for acne.\n\nSyntopix sees a clear strategic benefit in pursuing both medical and cosmetic\napplications for its library of products for the potential treatment of acne.\nThe cosmetic sector offers Syntopix the opportunity for early revenues as the\nregulatory and product approval process is shorter than for medicines. The\nglobal market size for these types of cosmetic products is estimated to be in\nexcess of $10 billion.\n\nBioskin will conduct the trials in more than 130 acne sufferers using Syntopix'\nlibrary compounds SYN 0126 and a combination of SYN 0126 with SYN 0091. The\ntrials, which will take place at a series of centres in Germany, will commence\nin the early summer and results are anticipated later in the year.\n\nThe trial compounds, all of which are suitable for use as cosmetics, are in line\nwith the Company's strategy of seeking to reduce risk by concentrating on the\nchange of use and novel combinations of known compounds with well documented\npharmacology and toxicity profiles.\n\nSteve Jones, Syntopix' CEO, commented: 'We are very pleased to have appointed\nBioskin, a contract research organisation focussed on dermatology, to carry out\ntrials on compounds that we believe have real potential as cosmetic treatments\nfor acne. Strategically we believe the cosmetic market is attractive as it gives\nthe Company the opportunity to receive early product revenues.'\n\n\nENDS\n\nFor further information please contact:\n\nSyntopix Group plc 0845 125 9204\nStephen Jones, Chief Executive Officer\nRod Adams, Chairman\n\nKBC Peel Hunt Ltd 020 7418 8900\nMegan MacIntyre\n\nBuchanan Communications 020 7466 5000\nMark Court/Mary-Jane Johnson/Catherine Breen\n\n\nNotes to editors\n\nAbout Syntopix Group plc\n\nSyntopix, a group focused on the discovery and development of drugs for the\ntopical treatment of dermatol...